Last reviewed · How we verify
Elidel (pimecrolimus 1%)
Pimecrolimus is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin.
Pimecrolimus is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin. Used for Atopic dermatitis (eczema), Allergic contact dermatitis, Seborrheic dermatitis.
At a glance
| Generic name | Elidel (pimecrolimus 1%) |
|---|---|
| Sponsor | St Joseph University, Beirut, Lebanon |
| Drug class | Calcineurin inhibitor (topical immunosuppressant) |
| Target | Calcineurin (protein phosphatase 2B) |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Immunology |
| Phase | Phase 3 |
Mechanism of action
Pimecrolimus binds to calcineurin and inhibits its phosphatase activity, preventing the dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the transcription of pro-inflammatory cytokines such as IL-2, TNF-α, and IFN-γ, thereby reducing local immune activation and inflammation in atopic dermatitis and other inflammatory skin conditions.
Approved indications
- Atopic dermatitis (eczema)
- Allergic contact dermatitis
- Seborrheic dermatitis
Common side effects
- Application site burning or irritation
- Pruritus
- Skin infection (secondary bacterial or viral)
- Folliculitis
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (PHASE3)
- 10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
- A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD) (PHASE1)
- Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.
- Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients (PHASE1)
- Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) (PHASE4)
- A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elidel (pimecrolimus 1%) CI brief — competitive landscape report
- Elidel (pimecrolimus 1%) updates RSS · CI watch RSS
- St Joseph University, Beirut, Lebanon portfolio CI